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The title compound (systematic name: 10,11-dihydro-5H-
dibenz[b,f]azepine-5-carboxamide), C15H14N2O, is shown to
crystallize as an orthorhombic polymorph to complement the
known monoclinic form. The molecular conformations of both
forms are very similar, involving a bent conformation for the
seven-membered azepine ring and an overall `butter¯y' shape.
The molecules assemble into chains by way of NÐH  O
bonds and NÐH   interactions in both crystal modi®ca-
tions. The two polymorphs appear to form due to different van
der Waals interactions between the layer-like sheets of
molecules.
Comment
Carbamazepine, (I), is an anticonvulsant agent with many
pharmaceutical and medicinal applications (Birkhimer et al.,
1985; Nagaraj et al., 2005). Compound (I) is of considerable
structural interest as it serves as a model compound for mol-
ecular-crystal polymorphism, with four crystalline forms
known (Grzesiak et al., 2003). It has been estimated (Henck et
al., 1997) that as many as one third of pharmaceutical solids
may display crystal polymorphism which can have a dramatic
effect on their physiological properties (Knapman, 2000).
The crystal structures of various derivatives of carbamaze-
pine have been reported (Himes et al., 1981; Lisgarten et al.,
1989; Hempel et al., 2005; Nagaraj et al., 2005; Johnston et al.,
2005). Recently, the crystal structure of 5-chlorocarbonyl-
10,11-dihydro-5H-dibenz[b,f]azepine, (II), was published
(Vijay et al., 2005). The structure of the title compound, 10,11-
dihydrocarbamazapine, (III), was reported by Bandoli et al.
(1992) to be monoclinic, space group P21/c. We report here a
second, orthorhombic (space group Pbca), modi®cation of
(III) (Table 1 and Fig. 1).
The geometric parameters for (III) fall within their
expected ranges (Allen et al., 1995). The dihedral angle
between the best planes of the two benzene rings (C1±C6 and
C9±C14) is 119.03 (4), compared with an equivalent value of
118.20 (12) [calculated with PLATON (Spek, 2003)] in the
monoclinic form of (III) (Bandoli et al., 1992). The Bandoli
paper cites this dihedral angle as 128, perhaps as the result of
a misprint. The central seven-membered azepine ring (C1/C6±
C9/C14/N1) in (I) adopts the so-called bent transition state
conformation (Hendrickson, 1967; Bocian & Strauss, 1977),
intermediate between the boat and chair forms of a classical
cycloheptane ring. In this conformation, ®ve atoms (C1/C6±
C8/N1) are almost coplanar [r.m.s. deviation from the best
plane = 0.042 AÊ ; maximum deviation = 0.050 (1) AÊ for atom
C7], and atoms C9 and C14 are substantially displaced from
the plane by 1.108 (2) and 1.149 (2) AÊ , respectively. This
conformation, commonly seen in 10,11-dihydro-
carbamazepines (Vijay et al., 2005), has approximate Cs
(mirror) symmetry, with the mirror plane passing through
atom C6 and the mid-point of the C9ÐC14 bond, if atom N1
takes on the identity of a C atom for this analysis. The bond-
angle sum of 359.7 about atom N1 in (III) indicates sp2
hybridization for this atom and the N1/C15/O1/N2 grouping is
statistically planar [r.m.s. deviation = 0.0004 AÊ ; maximum
deviation = 0.0008 (11) AÊ for atom C15]. Overall, this azepine
conformation results in the molecule of (III) taking on a
`butter¯y' shape, as previously described for related carba-
mazepine derivatives (Vijay et al., 2005).
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Figure 1
A view of (III), showing the atom-labelling scheme. Displacement
ellipsoids are drawn at the 50% probability level and H atoms are shown
as small spheres of arbitray radii.
Figure 2
Detail of the structure of (III), showing a chain resulting from NÐH  O
and NÐH   interactions. All C-bound H atoms have been omitted for
clarity. [Symmetry codes are as in Table 2; additionally: (iii) x ÿ 1, y, z.]
The ±NH2 unit in (III) makes only one NÐH  O hydrogen
bond (Table 2). The H  O separation of 2.206 (18) AÊ suggests
that it is a relatively weak interaction. This bond links the
molecules into one-dimensional strings propagating in the a
direction. The second H atom points towards the centroid of a
nearby C9±C14 benzene ring (Fig. 2) and the resulting almost
linear NÐH   interaction (Rodham et al., 1993) thus
appears to help to stabilize the [100] chains.
Any ± stacking in (III) must be extremely weak, with the
shortest aromatic ring centroid±centroid separation being
4.82 AÊ (Spek, 2003). A very similar situation occurs for the
monoclinic polymorph (the shortest centroid±centroid sep-
aration is 4.78 AÊ ). This contrasts strongly with the situation in
(II), where no conventional hydrogen bonds are possible and
± stacking dominates the crystal packing.
The monoclinic form of (III) shows a very similar molecular
conformation to the title compound. It possesses the same
extended chain structure (propagating in the [010] direction),
consolidated by NÐH  O and NÐH   interactions as in
the orthorhombic form of (III). It differs in the arrangements
of adjacent sheets of chains with respect to the monoclinic
[001] and orthorhombic [001] directions. In the monoclinic
phase, adjacent pseudo-sheets in the c direction all show the
same orientation of the carbamoyl groupings (Fig. 3a). In the
orthorhombic form (Fig. 3b), adjacent sheets of carbamoyl
groupings alternate in a zigzag pattern. Inversion symmetry
generates the adjacent [001] layer in the monoclinic phase and
a glide operation performs the same task in the orthorhombic
modi®cation. No unusually short inter-sheet [001] inter-
molecular contacts were identi®ed in either phase.
The fact that the density of 1.352 Mg mÿ3 of orthorhombic
(III) reported here is signi®cantly greater than that of the
monoclinic form (1.301 Mg mÿ3) suggests that the new form of
(III) may be a more thermodynamically stable polymorph.
Monoclinic (III) was recrystallized from ethanol, resulting in
parallelepiped-shaped crystals. Thus, it seems likely (and
typical) that the solvent plays an important role in deter-
mining the polymorph that results.
Experimental
The sample of (III) was kindly supplied by Jubilant Organosys,
Nanjangud, India. The compound was recrystallized from acetonitrile
(m.p. 473 K).
Crystal data
C15H14N2O
Mr = 238.28
Orthorhombic, Pbca
a = 9.0592 (4) AÊ
b = 10.3156 (5) AÊ
c = 25.0534 (12) AÊ
V = 2341.27 (19) AÊ 3
Z = 8
Dx = 1.352 Mg m
ÿ3
Mo K radiation
Cell parameters from 3022
re¯ections
 = 2.9±27.5
 = 0.09 mmÿ1
T = 120 (2) K
Block, colourless
0.28  0.24  0.18 mm
Data collection
Nonius KappaCCD area-detector
diffractometer
! and ’ scans
Absorption correction: multi-scan
(SADABS; Bruker, 2003)
Tmin = 0.976, Tmax = 0.987
16158 measured re¯ections
2680 independent re¯ections
2289 re¯ections with I > 2(I)
Rint = 0.042
max = 27.6

h = ÿ11! 8
k = ÿ13! 12
l = ÿ32! 32
Re®nement
Re®nement on F 2
R[F 2 > 2(F 2)] = 0.042
wR(F 2) = 0.108
S = 1.09
2680 re¯ections
169 parameters
H atoms treated by a mixture of
independent and constrained
re®nement
w = 1/[2(Fo
2) + (0.0384P)2
+ 1.5004P]
where P = (Fo
2 + 2Fc
2)/3
(/)max < 0.001
max = 0.24 e AÊ
ÿ3
min = ÿ0.20 e AÊ ÿ3
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Figure 3
(a) Unit-cell packing in the monoclinic form of (III), viewed approxi-
mately down [100]. Displacement ellipsoids are drawn at the 50%
probability level and all H atoms have been omitted for clarity. (b) Unit-
cell packing in the orthorhombic form of (III), viewed approximately
down [010]. Displacement ellipsoids are drawn at the 30% probability
level and all H atoms have been omitted for clarity [redrawn from
Bandoli et al. (1992)].
Table 1
Selected torsion angles ().
N1ÐC1ÐC6ÐC7 ÿ4.2 (2)
C1ÐC6ÐC7ÐC8 ÿ4.4 (2)
C6ÐC7ÐC8ÐC9 62.06 (16)
C7ÐC8ÐC9ÐC14 ÿ70.51 (15)
C8ÐC9ÐC14ÐN1 ÿ2.76 (17)
C6ÐC1ÐN1ÐC14 ÿ52.01 (17)
C9ÐC14ÐN1ÐC1 73.18 (16)
Table 2
Hydrogen-bond geometry (AÊ , ).
Cg1 is the centroid of the C9±C14 ring at (ÿ0.3474, 0.3861, 0.3981).
DÐH  A DÐH H  A D  A DÐH  A
N2ÐH1  Cg1i 0.887 (18) 2.86 3.75 173
N2ÐH2  O1ii 0.915 (18) 2.206 (18) 2.8970 (16) 131.7 (14)
Symmetry codes: (i) x  12;ÿy 12;ÿz 1; (ii) xÿ 12;ÿy 12;ÿz 1.
The N-bound H atoms were located in a difference map and their
positions were freely re®ned. The C-bound H atoms were positioned
geometrically, with CÐH distances in the range 0.95±0.99 AÊ , and
re®ned as riding. The constraint Uiso(H) = 1.2Ueq(carrier) was applied
in all cases.
Data collection: COLLECT (Nonius, 1998); cell re®nement:
SCALEPACK (Otwinowski & Minor, 1997); data reduction:
DENZO (Otwinowski & Minor, 1997), SCALEPACK and SORTAV
(Blessing, 1995); program(s) used to solve structure: SHELXS97
(Sheldrick, 1997); program(s) used to re®ne structure: SHELXL97
(Sheldrick, 1997); molecular graphics: ORTEP-3 (Farrugia, 1997);
software used to prepare material for publication: SHELXL97.
Supplementary data for this paper are available from the IUCr electronic
archives (Reference: FG3005). Services for accessing these data are
described at the back of the journal.
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